BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term follow-up results from two pivotal Phase 3 studies of IMBRUVICA® (ibrutinib) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), a type of non-Hodgkin lymphoma and the most common form of leukemia in adults

Deborah Hospital Foundation’s sound fiscal management practices and commitment to accountability and transparency have earned a 4 out of 4-star rating from Charity Navigator, America’s largest independent charity evaluator.

The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of accelerating the time it takes to identify and develop potential new medicines.

Sub-Population Analysis Demonstrates High Rates of Durable Response and Overall Survival Regardless of Age at Two Years Post-Treatment

SS&C is a global provider of software and software-enabled services for the financial services and healthcare industries

Takeda’s Growing Lung Portfolio is Driven by a Dedication to Developing Innovative Therapies for People Living with NSCLC

The data demonstrate that melflufen may offer positive disease stabilization and favorable time to next treatment (TTNT) outcomes in heavily-pretreated patients with relapsed/refractory multiple myeloma (RRMM).

The verdict was delivered in the Philadelphia Court of Common Pleas on May 17, 2019 and also included $50 million in punitive damages.

Waiting weeks to see an elite physician is a thing of the past. Members now get a curated team of top physicians and a care coordination team to facilitate their needs.

New Orders, Production, and Employment Growing